Trial Profile
The single-center clinical study of apatinib tablet for the treatment of recurrent refractory chordoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Sep 2020
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Chordoma
- Focus Therapeutic Use
- 01 Sep 2020 Results (N=30), of intention to treat analysis, published in the Lancet Oncology
- 30 Nov 2017 New trial record